Compounds > carmofur
Page last updated: 2024-10-24

carmofur and Aprosodia

carmofur has been researched along with Aprosodia in 1 studies

Research Excerpts

ExcerptRelevanceReference
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg."7.67[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg."3.67[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shiraishi, K1
Kubo, Y1
Majima, Y1
Sato, K1
Sakemi, T1
Sakai, T1
Hirai, K1
Ninomiya, F1
Abe, M1
Tanikawa, K1

Other Studies

1 other study available for carmofur and Aprosodia

ArticleYear
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorou

1984